A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.
Latest Information Update: 16 Jul 2019
At a glance
- Drugs DSM 265 (Primary)
- Indications Malaria
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 21 Aug 2015 According to the Australian New Zealand Clinical Trials Registry Record, status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Aug 2015 New trial record